Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Korean Soc Radiol ; 85(3): 668-675, 2024 May.
Article in Korean | MEDLINE | ID: mdl-38873388

ABSTRACT

Aortic anastomotic leak is an uncommon complication after ascending aortic replacement for acute aortic dissection. Redo-surgery is the traditional standard treatment despite high mortality and morbidity. Recently, endovascular treatment has been attempted as an alternative approach in a few case reports. Here, we present two cases of aortic anastomotic leak due to suture line dehiscence after aortic graft replacement for type A aortic dissection, which were successfully treated by coil with subsequent N-butyl cyanoacrylate embolization and an Amplatzer™ vascular plug.

2.
Cryobiology ; 115: 104889, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38513998

ABSTRACT

Chimeric antigen receptor (CAR) T-cell therapies are increasingly adopted as a commercially available treatment for hematologic and solid tumor cancers. As CAR-T therapies reach more patients globally, the cryopreservation and banking of patients' leukapheresis materials is becoming imperative to accommodate intra/inter-national shipping logistical delays and provide greater manufacturing flexibility. This study aims to determine the optimal temperature range for transferring cryopreserved leukapheresis materials from two distinct types of controlled rate freezing systems, Liquid Nitrogen (LN2)-based and LN2-free Conduction Cooling-based, to the ultracold LN2 storage freezer (≤-135 °C), and its impact on CAR T-cell production and functionality. Presented findings demonstrate that there is no significant influence on CAR T-cell expansion, differentiation, or downstream in-vitro function when employing a transfer temperature range spanning from -30 °C to -80 °C for the LN2-based controlled rate freezers as well as for conduction cooling controlled rate freezers. Notably, CAR T-cells generated from cryopreserved leukapheresis materials using the conduction cooling controlled rate freezer exhibited suboptimal performance in certain donors at transfer temperatures lower than -60 °C, possibly due to the reduced cooling rate of lower than 1 °C/min and extended dwelling time needed to reach the final temperatures within these systems. This cohort of data suggests that there is a low risk to transfer cryopreserved leukapheresis materials at higher temperatures (between -30 °C and -60 °C) with good functional recovery using either controlled cooling system, and the cryopreserved materials are suitable to use as the starting material for autologous CAR T-cell therapies.


Subject(s)
Cryopreservation , Immunotherapy, Adoptive , Leukapheresis , T-Lymphocytes , Cryopreservation/methods , Leukapheresis/methods , Humans , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Immunotherapy, Adoptive/methods , Receptors, Chimeric Antigen , Temperature , Freezing , Cell Culture Techniques/methods
3.
J Ethnopharmacol ; 120(2): 215-9, 2008 Nov 20.
Article in English | MEDLINE | ID: mdl-18790041

ABSTRACT

AIM OF STUDY: This study was performed to elicit the effectiveness of bee venom (BV), a traditional immunosuppressive Korean acupuncture agent, on the maturation of dendrtic cells (DCs). MATERIALS AND METHODS: Immature dendritic cells (iDCs) were generated from mouse bone marrow cells with GM-CSF. After 10 days of initial differentiation, DCs were activated with lipopolysaccharides (LPS) for another 48h in the presence or absence of BV. Surface molecule analysis, intracytoplasmic staining of cytokines, FITC-conjugated antigen uptake, and transwell migration assays were conducted with iDCs and activated DCs. RESULTS: Up-regulation of costimulatory molecules, typical of mature DCs (mDCs) was inhibited by addition of BV. Pro-inflammatory cytokines were also found to be reduced with BV treatment in LPS-stimulated DC. A decrease in antigen uptake upon the maturation of DC was reversed in low dose BV treated mDC. In addition, BV treated mDC demonstrated reduced directional migration in response to CCL21, a lymphoid chemokine which directs mDC. CONCLUSIONS: BV may have a therapeutic effect an on abnormally activated immune status, such as autoimmune rheumatoid arthritis, through an immune-modulatory effect on DC.


Subject(s)
Antigens, CD/drug effects , Bee Venoms/pharmacology , Dendritic Cells/drug effects , Immunosuppressive Agents/pharmacology , Animals , Antigens, CD/immunology , Bee Venoms/administration & dosage , Bone Marrow Cells/metabolism , Cell Differentiation/drug effects , Chemokine CCL21/administration & dosage , Dendritic Cells/immunology , Dose-Response Relationship, Drug , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Immunosuppressive Agents/administration & dosage , Inflammation Mediators/metabolism , Lipopolysaccharides , Medicine, Korean Traditional , Mice , Mice, Inbred C57BL , Up-Regulation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...